IRIS Accounts Production v25.1.3.33 07984277 Board of Directors 1.4.24 31.3.25 31.3.25 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh079842772024-03-31079842772025-03-31079842772024-04-012025-03-31079842772023-03-31079842772023-04-012024-03-31079842772024-03-3107984277ns15:EnglandWales2024-04-012025-03-3107984277ns14:PoundSterling2024-04-012025-03-3107984277ns10:Director12024-04-012025-03-3107984277ns10:PrivateLimitedCompanyLtd2024-04-012025-03-3107984277ns10:SmallEntities2024-04-012025-03-3107984277ns10:AuditExempt-NoAccountantsReport2024-04-012025-03-3107984277ns10:SmallCompaniesRegimeForDirectorsReport2024-04-012025-03-3107984277ns10:SmallCompaniesRegimeForAccounts2024-04-012025-03-3107984277ns10:FullAccounts2024-04-012025-03-3107984277ns10:Director22024-04-012025-03-3107984277ns10:Director32024-04-012025-03-3107984277ns10:CompanySecretary12024-04-012025-03-3107984277ns10:RegisteredOffice2024-04-012025-03-3107984277ns5:CurrentFinancialInstruments2025-03-3107984277ns5:CurrentFinancialInstruments2024-03-3107984277ns5:ShareCapital2025-03-3107984277ns5:ShareCapital2024-03-3107984277ns5:RetainedEarningsAccumulatedLosses2025-03-3107984277ns5:RetainedEarningsAccumulatedLosses2024-03-3107984277ns5:FurnitureFittings2024-04-012025-03-3107984277ns5:ComputerEquipment2024-04-012025-03-3107984277ns5:FurnitureFittings2024-03-3107984277ns5:ComputerEquipment2024-03-3107984277ns5:FurnitureFittings2025-03-3107984277ns5:ComputerEquipment2025-03-3107984277ns5:FurnitureFittings2024-03-3107984277ns5:ComputerEquipment2024-03-3107984277ns5:WithinOneYearns5:CurrentFinancialInstruments2025-03-3107984277ns5:WithinOneYearns5:CurrentFinancialInstruments2024-03-31
REGISTERED NUMBER: 07984277 (England and Wales)














THERAPEUTIC CHALLENGES ANALYSIS LIMITED

UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2025






THERAPEUTIC CHALLENGES ANALYSIS LIMITED (REGISTERED NUMBER: 07984277)






CONTENTS OF THE FINANCIAL STATEMENTS
for the Year Ended 31 March 2025




Page

Company Information 1

Statement of Financial Position 2

Notes to the Financial Statements 4


THERAPEUTIC CHALLENGES ANALYSIS LIMITED

COMPANY INFORMATION
for the Year Ended 31 March 2025







DIRECTORS: N Touchot
Mrs M Touchot
Ms B Nathwani





SECRETARY: Mrs M Touchot





REGISTERED OFFICE: 5 Imperial Court
Laporte Way
Luton
Bedfordshire
LU4 8FE





REGISTERED NUMBER: 07984277 (England and Wales)





ACCOUNTANTS: Miller & Co
Chartered Accountants
5 Imperial Court
Laporte Way
Luton
Bedfordshire
LU4 8FE

THERAPEUTIC CHALLENGES ANALYSIS LIMITED (REGISTERED NUMBER: 07984277)

STATEMENT OF FINANCIAL POSITION
31 March 2025

2025 2024
Notes £    £    £   
FIXED ASSETS
Tangible assets 5 3,144 1,550
Investments 6 14,259 14,259
17,403 15,809

CURRENT ASSETS
Debtors 7 17,401 22,333
Cash at bank 323,778 385,663
341,179 407,996
CREDITORS
Amounts falling due within one year 8 60,142 27,593
NET CURRENT ASSETS 281,037 380,403
TOTAL ASSETS LESS CURRENT
LIABILITIES

298,440

396,212

PROVISIONS FOR LIABILITIES - 388
NET ASSETS 298,440 395,824

CAPITAL AND RESERVES
Called up, paid and allotted share capital 2 2
Retained earnings 298,438 395,822
SHAREHOLDERS' FUNDS 298,440 395,824

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2025 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

THERAPEUTIC CHALLENGES ANALYSIS LIMITED (REGISTERED NUMBER: 07984277)

STATEMENT OF FINANCIAL POSITION - continued
31 March 2025


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 19 June 2025 and were signed on its behalf by:





N Touchot - Director


THERAPEUTIC CHALLENGES ANALYSIS LIMITED (REGISTERED NUMBER: 07984277)

NOTES TO THE FINANCIAL STATEMENTS
for the Year Ended 31 March 2025

1. STATUTORY INFORMATION

Therapeutic Challenges Analysis Limited is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling, rounded to the nearest pound.

2. STATEMENT OF COMPLIANCE

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006.

3. ACCOUNTING POLICIES

Basis of preparing the financial statements
The financial statements have been prepared under the historical cost convention.

Income recognition
Income is recognised when goods/services have been delivered to customers such that risks and rewards of ownership have transferred to them.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Fixtures and fittings - 25% on reducing balance
Computer equipment - 33% on cost

Taxation
Current tax represents the amount of tax payable or receivable in respect of the taxable profit (or loss) for the current or past reporting periods. It is measured at the amount expected to be paid or recovered using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax represents the future tax consequences of transactions and events recognised in the financial statements of current and previous periods. It is recognised in respect of all timing differences, with certain exceptions. Timing differences are differences between taxable profits and total comprehensive income as stated in the financial statements that arise from the inclusion of income and expense in tax assessments in periods different from those in which they are recognised in the financial statements. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date that are expected to apply to the reversal of timing differences. Deferred tax on revalued non-depreciable tangible fixed assets and investment properties is measured using the rates and allowances that apply to the sale of the asset.

Foreign currencies
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the statement of financial position date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

THERAPEUTIC CHALLENGES ANALYSIS LIMITED (REGISTERED NUMBER: 07984277)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the Year Ended 31 March 2025

3. ACCOUNTING POLICIES - continued

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Investments
Investments are recognised initially at cost which is normally the transaction price excluding transaction costs.

Subsequently, fixed asset investments are measured at cost less impairment on the basis that they represent shares in entities that are not publicly traded and the fair value cannot otherwise be measured reliably.

Government grants
Government grants are recognised using the performance model and are recognised in other income when the grants proceeds are received or receivable.

4. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 2 (2024 - 2 ) .

5. TANGIBLE FIXED ASSETS
Fixtures
and Computer
fittings equipment Totals
£    £    £   
COST
At 1 April 2024 4,723 29,881 34,604
Additions - 3,233 3,233
Disposals - (12,208 ) (12,208 )
At 31 March 2025 4,723 20,906 25,629
DEPRECIATION
At 1 April 2024 3,929 29,125 33,054
Charge for year 200 1,439 1,639
Eliminated on disposal - (12,208 ) (12,208 )
At 31 March 2025 4,129 18,356 22,485
NET BOOK VALUE
At 31 March 2025 594 2,550 3,144
At 31 March 2024 794 756 1,550

6. FIXED ASSET INVESTMENTS

2025 2024
£    £   
Shares held in SAS Moodsights - -
Other investments 14,260 14,260
14,260 14,260
Shares held in SAS Moodsights, costing £19,702 were fully impaired during the year ended 31/03/2017.
Other investments are recognised at cost.

THERAPEUTIC CHALLENGES ANALYSIS LIMITED (REGISTERED NUMBER: 07984277)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the Year Ended 31 March 2025

7. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025 2024
£    £   
Trade debtors 16,449 -
Other debtors 952 22,333
17,401 22,333

8. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025 2024
£    £   
Trade creditors 11,434 -
Taxation and social security - 688
Other creditors 48,708 26,905
60,142 27,593

9. RELATED PARTY DISCLOSURES

The directors operate a loan account with the company. During the financial year, additional loan in aggregate of £21,769 were made to the company by the directors.

The balance owed to the directors at the year end was £46,049